Rehap Investigators

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5573600/rehap-investigators-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148 papers	2,271 citations	19 h-index	43 g-index
205 ext. papers	2,937 ext. citations	3.4 avg, IF	4.67 L-index

#	Paper	IF	Citations
148	An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension.. *Pulmonary Circulation*, **2022**, 12, e12024	2.7	3
147	Tromboendarterectomía pulmonar en pacientes sintomáticos con enfermedad tromboembólica crónica sin hipertensión arterial pulmonar. *Cirugia Cardiovascular*, **2022**, 29, 79-81	0.1	
146	Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience.. *Annals of Cardiothoracic Surgery*, **2022**, 11, 151-160	4.7	0
145	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.. *Scientific Reports*, **2022**, 12, 5289	4.9	0
144	The role of cardiopulmonary exercise testing in identifying and monitoring pulmonary veno-oclusive disease: a case report with ING.. *European Heart Journal - Case Reports*, **2022**, 6, ytac138	0.9	
143	Description of Two New Cases of AQP1 Related Pulmonary Arterial Hypertension and Review of the Literature. *Genes*, **2022**, 13, 927	4.2	1
142	Expanding the Evidence of a Semi-Dominant Inheritance in Associated with Pulmonary Arterial Hypertension. *Cells*, **2021**, 10,	7.9	2
141	Complications associated with peripherally inserted central catheters and Hickman®in patients with advanced pulmonary hypertension treated with intravenous prostanoids. *Respiratory Medicine*, **2021**, 189, 106649	4.6	
140	Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. *Catheterization and Cardiovascular Interventions*, **2021**, 98, 691-700	2.7	5
139	The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. *European Respiratory Journal*, **2021**, 57,	13.6	1
138	Novel and Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. *Frontiers in Medicine*, **2021**, 8, 625763	4.9	5
137	Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations. *Kardiologia Polska*, **2021**, 79, 386-392	0.9	2
136	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. *New England Journal of Medicine*, **2021**, 384, 1204-1215	59.2	54
135	Hipertensión pulmonar tromboembólica crónica en España: una década de cambio. *Revista Espanola De Cardiologia*, **2021**, 74, 384-392	1.5	2
134	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. *Orphanet Journal of Rare Diseases*, **2021** , 16, 196	4.2	4
133	Novel Genetic and Molecular Pathways in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. *Cells*, **2021**, 10,	7.9	4
132	Fístula entre bronquio y arteria pulmonar. Una grave complicación de la angioplastia pulmonar en la hipertensión pulmonar tromboembólica crónica. *Revista Espanola De Cardiologia*, **2021**, 74, 548-549	1.5	

131	COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?. *Annals of the American Thoracic Society*, **2021**, 18, 1080-1081	4.7	0
130	Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure. *Circulation: Heart Failure*, **2021**, 14, e008166	7.6	3
129	Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry. *Internal Medicine Journal*, **2021**, 51, 355-365	1.6	7
128	Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 74, 384-392	0.7	3
127	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2021**, 178, 106220	4.6	10
126	Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Veno-Occlusive Disease: Certainties and Uncertainties. *Diagnostics*, **2021**, 11,	3.8	2
125	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival. *Journal of the American Heart Association*, **2021**, 10, e019949	6	3
124	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. *Expert Review of Respiratory Medicine*, **2021**, 15, 493-504	3.8	2
123	From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?. *Advances in Therapy*, **2021**, 38, 1860-1875	4.1	0
122	Giant pulmonary artery aneurysm in pulmonary arterial hypertension. *Archivos De Bronconeumologia*, **2021**, 57, 541-541	0.7	
121	Left main coronary artery stent destructuring by a pulmonary artery aneurysm. *Cardiovascular Revascularization Medicine*, **2021**,	1.6	
120	El papel de la genética en la hipertensión arterial pulmonar asociada con cardiopatías congénitas. *Revista Espanola De Cardiologia*, **2021**, 74, 884-886	1.5	0
119	The role of genetics in pulmonary arterial hypertension associated with congenital heart disease. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 74, 884-886	0.7	
118	Tromboendarterectomía pulmonar en pacientes con hipertensión pulmonar tromboembólica crónica y afectación distal. *Cirugia Cardiovascular*, **2020**, 27, 230-235	0.1	
117	Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. *BMC Pulmonary Medicine*, **2020**, 20, 154	3.5	
116	Clinical course of COVID-19 in pulmonary arterial hypertension patients. *Revista Espanola De Cardiologia (English Ed)*, **2020**, 73, 775-778	0.7	5
115	Giant T Wave Inversion and Dyspnea in the Time of Coronavirus Pandemic. *Circulation*, **2020**, 142, 906-908	16.7	0
114	Heart Transplantation in a Distant Island Population: Accessibility and Outcomes in Patients From the Canary Islands Transplanted in Madrid. *Transplantation*, **2020**, 104, 223-226	1.8	

113	Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4. *PLoS ONE*, **2020**, 15, e0232216	3.7	10
112	Influence of long-standing pulmonary arterial hypertension and its severity on pulmonary artery aneurysm development. *Heart and Vessels*, **2020**, 35, 1290-1298	2.1	0
111	Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. *Genes*, **2020**, 11,	4.2	10
110	Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension. *Journal of Clinical Medicine*, **2020**, 9,	5.1	11
109	FRI0242 IMPACT OF PULMONARY ARTERIAL HYPERTENSION WITH OR WITHOUT INTERSTITIAL LUNG DISEASE ON SCLERODERMA: A RETROSPECTIVE COHORT STUDY FROM THE NATIONWIDE SPANISH SCLERODERMA (RESCLE) AND PULMONARY ARTERIAL HYPERTENSION (REHAP) REGISTRIES. *Annals of the Rheumatic Diseases*, **2020**, 79, 705.2-705	2.4	
108	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. *ERJ Open Research*, **2020**, 6,	3.5	14
107	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. *Diagnostics*, **2020**, 10,	3.8	12
106	Unexpected Favourable Course of Coronavirus Disease 2019 in Chronic Thromboembolic Pulmonary Hypertension Patients. *Archivos De Bronconeumologia*, **2020**, 56, 749-752	0.7	4
105	Feasibility of a Noninvasive Operability Assessment in Chronic Thromboembolic Pulmonary Hypertension under Real-World Practice. *Diagnostics*, **2020**, 10,	3.8	1
104	Safety of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension with Concomitant Novel Oral Anticoagulants or Vitamin K Antagonist Use: Data from the EXPERT Registry **2020**,		2
103	Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients. *Scientific Reports*, **2020**, 10, 15135	4.9	7
102	Inverse cardiac tamponade in severe pulmonary hypertension. *Medicina Clínica*, **2020**, 154, 287	1	
101	Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
100	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2020**, 177, 106241	4.6	4
99	Giant Pulmonary Artery Aneurysm in Pulmonary Arterial Hypertension. *Archivos De Bronconeumologia*, **2020**, 57, 541-541	0.7	
98	Evaluation of a nurse-led intervention program in heart failure: A randomized trial. *Medicina Clínica*, **2019**, 152, 431-437	1	3
97	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. *European Journal of Heart Failure*, **2019**, 21, 1383-1397	12.3	20
96	Exercise Benefits in Pulmonary Hypertension. *Journal of the American College of Cardiology*, **2019**, 73, 2906-2907	15.1	2

95	Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). *Pulmonary Circulation*, **2019**, 9, 2045894019846433	2.7	16
94	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 224-232	0.7	7
93	Soporte circulatorio con oxigenador extracorpﾣeo de membrana durante el embarazo en la enfermedad venooclusiva pulmonar. *Revista Espanola De Cardiologia*, **2019**, 72, 174-175	1.5	3
92	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. *European Respiratory Journal*, **2019**, 54,	13.6	13
91	Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag. *Archivos De Bronconeumologia*, **2019**, 55, 393-394	0.7	0
90	Safety of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension: Final Data Cut from the EXPERT Registry **2019**,		3
89	Vitamin D deficiency among patients with pulmonary hypertension. *BMC Pulmonary Medicine*, **2019**, 19, 258	3.5	6
88	Management of incidentally diagnosed pulmonary artery dissection in patients with pulmonary arterial hypertension. *European Journal of Cardio-thoracic Surgery*, **2019**, 56, 210-212	3	4
87	Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension. *American Journal of Cardiology*, **2019**, 123, 474-481	3	8
86	Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. *Archivos De Bronconeumologia*, **2019**, 55, 102-103	0.7	
85	Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension. *Journal of Physiology*, **2019**, 597, 1087-1101	3.9	18
84	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. *International Journal of Cardiology*, **2019**, 275, 158-164	3.2	7
83	Extracorporeal Membrane Oxygenation Support During Pregnancy in Pulmonary Veno-occlusive Disease. *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 174-175	0.7	
82	Angioplastia pulmonar con balﾣ en la hipertensiﾣ pulmonar tromboembﾣica crﾣica no operable. Estudio observacional en una unidad de referencia. *Revista Espanola De Cardiologia*, **2019**, 72, 224-232	1.5	11
81	Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2018**, 37, 182-183	5.8	
80	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. *Archivos De Bronconeumologia*, **2018**, 54, 205-215	0.7	17
79	Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience. *Transplantation Proceedings*, **2018**, 50, 1496-1503	1.1	10
78	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. *European Heart Journal*, **2018**, 39, 1255-1264	9.5	105

77	Selecciõ de lo mejor del aõ 2017 en hipertensiõ pulmonar. *Revista Espanola De Cardiologia*, **2018**, 71, 299-300	1.5	
76	Manejo de la hipertensiõ pulmonar tromboembõica crõica. Experiencia de un centro de referencia nacional. *Cirugia Cardiovascular*, **2018**, 25, 77-85	0.1	1
75	Selection of the Best of 2017 in Pulmonary Hypertension. *Revista Espanola De Cardiologia (English Ed)*, **2018**, 71, 299-300	0.7	
74	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. *Archivos De Bronconeumologia*, **2018**, 54, 205-215	0.7	8
73	Expresividad variable de una mutaciõ fundadora en el gen EIF2AK4 en pacientes con enfermedad venooclusiva pulmonar hereditaria. Impacto en la supervivencia. *Revista Espanola De Cardiologia*, **2018**, 71, 86-94	1.5	9
72	Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival. *Revista Espanola De Cardiologia (English Ed)*, **2018**, 71, 86-94	0.7	3
71	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. *Seminars in Arthritis and Rheumatism*, **2018**, 47, 870-876	5.3	4
70	Physical activity levels are low in patients with pulmonary hypertension. *Annals of Translational Medicine*, **2018**, 6, 205	3.2	9
69	Letter by Hernandez-Gonzalez et al Regarding Article, "Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension". *Circulation*, **2018**, 137, 2411-2412	16.7	2
68	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Medicina Cõica*, **2017**, 148, 265-270	1	9
67	Myocardial injury in severe heritable pulmonary veno-occlusive disease. *Journal of Heart and Lung Transplantation*, **2017**, 36, 818-820	5.8	
66	Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. *International Journal of Cardiology*, **2017**, 231, 277-283	3.2	50
65	The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. *Expert Review of Respiratory Medicine*, **2017**, 11, 491-503	3.8	39
64	Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 915-923	0.7	4
63	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. *Medicina Cõica (English Edition)*, **2017**, 148, 265-270	0.3	
62	Pulmonary endarterectomy outputs in chronic thromboembolic pulmonary hypertension. *Medicina Cõica*, **2017**, 149, 1-8	1	6
61	La evoluciõ de la hipertensiõ arterial pulmonar a´lo´largo de´30´aõs: experiencia de´un´centro de referencia. *Revista Espanola De Cardiologia*, **2017**, 70, 915-923	1.5	19
60	Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class. *Data in Brief*, **2017**, 12, 37-41	1.2	3

59	Left Main Extrinsic Compression in Pulmonary Arterial Hypertension: From Identification to Percutaneous Coronary Intervention Optimization. *Journal of the American College of Cardiology*, **2017**, 70, 2459-2460	15.1	3
58	Lung and heart-lung transplantation in pulmonary arterial hypertension. *PLoS ONE*, **2017**, 12, e0187811	3.7	3
57	Pulmonary endarterectomy outputs in chronic thromboembolic pulmonary hypertension. *Medicina Clínica (English Edition)*, **2017**, 149, 1-8	0.3	
56	Reply. *Medicina Clínica*, **2017**, 149, 320-321	1	
55	Founder Mutation C.3344C>t(p.Pro1115Leu) in the EIF2KA4 Gene in Iberian Romani Patients With Pulmonary Veno-Occlusive Disease: A Warning for our Daily Practice. *Archivos De Bronconeumologia* , **2016**, 52, 444-445	0.7	2
54	Fibrosing mediastinitis, an unusual clinical entity reminding chronic thromboembolic pulmonary hypertension. *Medicina Clínica (English Edition)*, **2016**, 147, 130-131	0.3	
53	Founder mutation C.3344C>t(p.Pro1115Leu) in the EIF2KA4 gene in iberian romani patients with pulmonary veno-occlusive disease: A warning for our daily practice. *Archivos De Bronconeumologia*, **2016**, 52, 444-5	0.7	4
52	Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. *International Journal of Cardiology*, **2016**, 203, 938-44	3.2	43
51	Use of Atrial Septostomy to Treat Severe Pulmonary Arterial Hypertension in Adults. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 78-81	0.7	3
50	Septostomía auricular en el tratamiento de la hipertensión arterial pulmonar grave del adulto. *Revista Espanola De Cardiologia*, **2016**, 69, 78-81	1.5	8
49	Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. *European Journal of Heart Failure*, **2016**, 18, 523-33	12.3	74
48	Análisis de los genes BMPR2, TBX4 y KCNK3 y correlación genotipo-fenotipo en pacientes y familias españolas con hipertensión arterial pulmonar. *Revista Espanola De Cardiologia*, **2016**, 69, 1011-1019	1.5	30
47	Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 1011-1019	0.7	15
46	A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. *Clinical Genetics*, **2015**, 88, 579-83	4	45
45	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Preliminary experience in Spain in a series of 7 patients. *Revista Espanola De Cardiologia (English Ed)*, **2015**, 68, 535-7	0.7	5
44	Pulmonary thromboendarterectomy in 106 patients with chronic thromboembolic pulmonary hypertension. *Archivos De Bronconeumologia*, **2015**, 51, 502-8	0.7	13
43	Predictive value of NT-proBNP combined with exercise capacity variables in pulmonary artery disease: Insights from a Spanish cohort. *International Journal of Cardiology*, **2015**, 186, 32-4	3.2	4
42	Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. *International Journal of Cardiology*, **2015**, 184, 717-723	3.2	56

41	Pulmonary Thromboendarterectomy in 106 Patients With Chronic Thromboembolic Pulmonary Hypertension. *Archivos De Bronconeumologia*, **2015**, 51, 502-508	0.7	6
40	Rationale and Design of a Randomized Controlled Trial Evaluating Whole Muscle Exercise Training Effects in Outpatients with Pulmonary Arterial Hypertension (WHOLEi+12). *Cardiovascular Drugs and Therapy*, **2015**, 29, 543-550	3.9	5
39	Angioplastia pulmonar con bal□n en la hipertensi□n pulmonar tromboemb□lica cr□nica no operable. Experiencia inicial en Espa□a en una serie de 7 pacientes. *Revista Espanola De Cardiologia*, **2015**, 68, 535-537	1.5	19
38	Pregnancy in Women With Structural Heart Disease: Experience in a Centre. *Revista Espanola De Cardiologia (English Ed)*, **2015**, 68, 1189-90	0.7	1
37	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. *American Heart Journal*, **2014**, 167, 210-7	4.9	46
36	Pulmonary Arterial Hypertension: Epidemiology and Registries. *Advances in Pulmonary Hypertension* , **2014**, 13, 21-26	0.5	5
35	Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series. *World Journal of Cardiology*, **2014**, 6, 495-501	2.1	13
34	Reply to letter to the editor "infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin". *Archivos De Bronconeumologia*, **2013**, 49, 217-8	0.7	
33	Pulmonary arterial hypertension: epidemiology and registries. *Journal of the American College of Cardiology*, **2013**, 62, D51-9	15.1	338
32	Reply to Letter to the Editor □nfections by Gram-Negative Bacilliin Patients with Pulmonary Arterial Hypertension Treated with Intravenous Prostacyclin□*Archivos De Bronconeumologia*, **2013**, 49, 217-218	0.7	
31	Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. *Archivos De Bronconeumologia*, **2013**, 49, 181-8	0.7	31
30	Demythologizing pulmonary artery aneurysm: prevalence and associated complications in a large pulmonary arterial hypertension population. *European Heart Journal*, **2013**, 34, P226-P226	9.5	4
29	Assessment of exercise response in chronic thromboembolic pulmonary hypertension by cardiopulmonary exercise testing. *European Heart Journal*, **2013**, 34, P3355-P3355	9.5	
28	The role of vascular obstruction site on pulsatile afterload in patients with pulmonary hypertension. *European Heart Journal*, **2013**, 34, P285-P285	9.5	
27	Compression of the left main coronary artery by a giant pulmonary artery aneurysm. *Circulation*, **2013**, 127, 1340-1	16.7	9
26	Predictors of pulmonary hypertension in patients with end-stage heart failure. *Congestive Heart Failure*, **2012**, 18, 212-6		3
25	High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil. *Archivos De Bronconeumologia*, **2012**, 48, 443-7	0.7	18
24	Steroid withdrawal during 5 years following heart transplantation, and the relationship between steroid dosage at 1-year follow-up and complications during the next 2 years: results from the RESTCO study. *Transplantation Proceedings*, **2012**, 44, 2631-4	1.1	6

23	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. *European Respiratory Journal*, **2012**, 40, 596-603	13.6	258
22	Induction treatment with monoclonal antibodies for heart transplantation. *Transplantation Reviews* , **2011**, 25, 21-6	3.3	7
21	Factors affecting the response to exercise in patients with severe pulmonary arterial hypertension. *Archivos De Bronconeumologia*, **2011**, 47, 10-6	0.7	3
20	Giant pulmonary artery aneurysm in a patient with vasoreactive pulmonary hypertension: a case report. *BMC Cardiovascular Disorders*, **2011**, 11, 64	2.3	15
19	Current diagnostic and prognostic assessment of pulmonary Hypertension. *Revista Espanola De Cardiologia (English Ed)*, **2010**, 63, 583-96	0.7	3
18	Complications of proximal pulmonary artery aneurysm in patients with severe pulmonary arterial hypertension. *Revista Espanola De Cardiologia (English Ed)*, **2010**, 63, 617-8	0.7	2
17	[Not Available]. *Revista Espanola De Cardiologia*, **2010**, 63, 617-8	1.5	10
16	Evaluaci diagn tica y pron tica actual de la hipertensi pulmonar. *Revista Espanola De Cardiologia*, **2010**, 63, 583-596	1.5	13
15	Iloprost different indications and different national experiences in treating pulmonary hypertension. *Clinical Research in Cardiology Supplements*, **2010**, 5, 19-23	3.1	
14	Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. *Transplantation Proceedings*, **2009**, 41, 2477-9	1.1	13
13	Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2009**, 28, 621-7	5.8	30
12	Est dares asistenciales en hipertensi pulmonar. *Archivos De Bronconeumologia*, **2008**, 44, 87-99	0.7	14
11	Standards of care in pulmonary hypertension. *Revista Espanola De Cardiologia*, **2008**, 61, 170-84	1.5	17
10	Extracorporeal membrane oxygenation as a bridge to emergency heart-lung transplantation in a patient with idiopathic pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2008**, 27, 466-8	5.8	66
9	Transition From Prostacyclin to Bosentan in Five Patients With Severe Pulmonary Hypertension: the Switch Is Possible. *Revista Espanola De Cardiologia (English Ed)*, **2006**, 59, 737-739	0.7	
8	Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. *European Journal of Heart Failure*, **2005**, 7, 1011-6	12.3	191
7	Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. *European Journal of Heart Failure*, **2004**, 6, 615-7	12.3	35
6	Efficacy of Oral Sildenafil as Rescue Therapy in Patients With Severe Pulmonary Arterial Hypertension Chronically Treated With Prostacyclin. Long-Term Results. *Revista Espanola De Cardiologia (English Ed)*, **2004**, 57, 946-951	0.7	2

5	Impact of diltiazem administration and cyclosporine levels on the incidence of acute rejection in heart transplant patients. *Transplant International*, **2003**, 16, 676-80	3	2
4	Steroid withdrawal in nonimmunologically selected heart transplant recipients. *Transplantation Proceedings*, **2002**, 34, 164-5	1.1	7
3	Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. *Journal of Heart and Lung Transplantation*, **2001**, 20, 942-8	5.8	80
2	Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. *Transplantation Proceedings*, **1999**, 31, 2515-6	1.1	7
1	Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation. *Transplantation Proceedings*, **1998**, 30, 1671-2	1.1	